XM không cung cấp dịch vụ cho cư dân của Mỹ.
S
S

Symrise


Tin tức

Symrise slips, analysts points to lack of beat, guidance hike

BUZZ-Symrise slips, analysts points to lack of beat, guidance hike ** Shares in Symrise SY1G.DE slip around 2% after it posted in-line H1 results and confirmed its guidance, with analysts noting that investors were likely expecting more ** "We believe the market was looking rather for a slight beat to the consensus," Konstantin Wiechert at Baader H
G
S
G

Symrise's half-year sales rise on fragrance business growth

UPDATE 2-Symrise's half-year sales rise on fragrance business growth H1 sales rise 6.3% year-on-year to 2.57 billion euros H1 EBITDA rises 11.5% to 529.8 million euros Sees 2024 organic growth at upper end of 5-7% guidance Adds CFO quote in paragraphs 5-6, share reaction in paragraph 8, analyst comments paragraph 9, division detail paragraph 11 By Antonis Pothitos Aug 1 (Reuters) - German flavour and fragrance maker Symrise SY1G.DE posted a 6.3% rise in its half-year sales on Thursday, in line w
G
K
L
S

Symrise H1 Sales Increase By 6.3%

BRIEF-Symrise H1 Sales Increase By 6.3% Aug 1 (Reuters) - SYMRISE AG SY1G.DE : H1 GROUP SALES INCREASE BY 6.3 % TO EUR 2,565 MILLION; ORGANIC GROWTH OF 11.5 % IN LONG TERM, COMPANY AIMS TO INCREASE ITS SALES TO EUR 7.5 TO 8.0 BILLION BY 2028 IN LONG TERM EBITDA MARGIN SHOULD REMAIN WITHIN A TARGET CORRIDOR OF 20 TO 23 % Source text for Eikon: ID:nE
S

Symrise posts 6% rise in half-year sales, meeting expectations

Symrise posts 6% rise in half-year sales, meeting expectations Aug 1 (Reuters) - German flavour and fragrance maker Symrise SY1G.DE posted a 6.3% rise in its half-year sales on Thursday, in line with estimates, driven by growth in both of its business areas. Symrise's revenue rose to 2.57 billion euros ($2.78 billion)in the January-June period from 2.41 billion a year earlier.
S

Dsm-firmenich shares jump after core earnings forecast hike

UPDATE 2-Dsm-firmenich shares jump after core earnings forecast hike Adds CEO quote from analyst call in paragraphs 6-8, share move in paragraph 2 By Dimitri Rhodes and Anna Peverieri July 30 (Reuters) - Dutch chemicals maker dsm-firmenich DSFIR.AS raised its core earnings forecast for 2024 on Tuesday, banking on savings from the restructuring of its vitamin business and continued integration of DSM and Firmenich's legacy businesses.
G
S
N

Dsm-firmenich raises forecast on vitamin business

Dsm-firmenich raises forecast on vitamin business July 30 (Reuters) - Dutch chemicals maker dsm-firmenich DSFIR.AS raised its annual core earnings forecast on Tuesday, helped by the vitamin transformation programme and improving business conditions. The company now sees adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) of around 2 billion euros ($2.16 billion) in 2024, up from the 1.9 billion euros previously forecast.
G
S

Germany corporate earnings week ahead

DIARY-Germany corporate earnings week ahead July 26 (Reuters) - Diary of Germany (.GDAXI) corporate earnings for the week ahead GERMANY EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 30-Jul-2024 NTS 1COV.DE Covestro AG Half Year 2024 Covestro AG Earnings Release 30-Jul-2024 BMO HEIG.DE Heidelberg Materials AG Half Year 2024 Heidelberg Materials AG Earnings Release 30-Jul-2024 04:30 AIR.PA Airbus SE Half Year 2024 Airbus SE Earnings Release 31-Jul-2024 AMC QGEN.N Qiagen NV Q2 20
A
A
B
F
M
P
S
S
V
V
Q
G

JPM sees a 'more balanced' H1 for European Staples

BUZZ-JPM sees a 'more balanced' H1 for European Staples ** J.P.Morgan expects a "more balanced" H1 for European staples ** Says risk of challenging demand environment and growth threat from weakening pricing and worse forex market are partially offset by better margin outcome and continued volumes improvement ** Adds H1 may also highlight risks in the U.S.
B
D
D
H
J
S
A
P

GS sees uneven recovery for European chemicals; ups Clariant, cuts Akzo

BUZZ-GS sees uneven recovery for European chemicals; ups Clariant, cuts Akzo ** Goldman Sachs favours consumer ingredient and gasses cos over diversified chemicals and paint makers based on pricing power, as the European chemicals sector faces an uneven recovery ** GS notes Europe's STOXX chemicals sub-index .SX4P is up 13% from its October 2023 tr
A
B
C
C
G
L
S
U
A
A

Bechtle AG, Centrica, Clariant AG

EUROPE RESEARCH ROUNDUP-Bechtle AG, Centrica, Clariant AG July 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bechtle AG, Centrica and Clariant AG, on Monday. HIGHLIGHTS * Akzo Nobel NV AKZO.AS : Goldman Sachs cuts to sell from neutral * Bechtle AG BC8G.DE : Exane BNP Paribas cuts to underperform from neutral * Centrica CNA.L : Berenberg raises to buy from hold * Clariant AG CLN.S : Goldman Sachs raises to buy from neutral * Fin
A
A
A
A
B
B
B
C
C
C
D
D
H
H
P
S
S
A
A
F
J

EU fines IFF for obstructing investigation of suspected fragrance cartel

EU fines IFF for obstructing investigation of suspected fragrance cartel BRUSSELS, June 24 (Reuters) - The European Commission said on Monday it had fined U.S. company International Flavors & Fragrances IFF.N (IFF) and its French affiliate 15.9 million euros ($17.05 million) for obstructing an inspection in an ongoing investigation of a suspected cartel in the supply of fragrances and fragrance ingredients.
G
S
I

Givaudan, National Grid, Schneider Electric

EUROPE RESEARCH ROUNDUP-Givaudan, National Grid, Schneider Electric June 18 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Givaudan, National Grid and Schneider Electric, on Tuesday. HIGHLIGHTS * Crest Nicholson Holdings Plc CRST.L : RBC raises target price to 250p from 175p * Givaudan SA GIVN.S : JP Morgan raises target price to CHF 4,200 from CHF 3,800 * National Grid NG.L : Barclays cuts target price to 1120p from 1365p * Schne
A
B
C
C
E
G
G
H
H
H
I
I
L
L
N
P
S
S
S
H
A
A
N
S
S
W

JPM puts Symrise on positive catalyst watch ahead of Q2

BUZZ-JPM puts Symrise on positive catalyst watch ahead of Q2 ** J.P.Morgan places Symrise SY1G.DE on positive catalyst watch into the German flavour and fragrance maker's Q2 results , expecting revenue growth at its Scent & Care division and good momentum behind margin rebuild ** Symrise's stock is up 1.4% in early Frankfurt trade ** JPM notes Symr
G
J
S

Adidas AG, Crest Nicholson Holdings, Standard Chartered

EUROPE RESEARCH ROUNDUP-Adidas AG, Crest Nicholson Holdings, Standard Chartered June 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas AG, Crest Nicholson Holdings and Standard Chartered, on Monday. HIGHLIGHTS * Adidas AG ADSGn.DE : JP Morgan raises target price to EUR 250 from EUR 240 * Bellway Plc BWY.L : JP Morgan raises target price to 2,790p from 2,780p * Crest Nicholson Holdings Plc CRST.L : Peel Hunt raises target pr
A
A
B
B
B
C
C
C
E
E
G
H
J
L
O
P
S
S
S
U
A
A
F
U

AB Dynamics, Etteplan, Wise

EUROPE RESEARCH ROUNDUP-AB Dynamics, Etteplan, Wise June 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AB Dynamics, Etteplan and Wise, on Friday. HIGHLIGHTS * AB Dynamics Plc ABDP.L : Berenberg re-initiates coverage With Buy rating; PT 2,620p * Crest Nicholson CRST.L : Barclays cuts target price to 230p from 258p * Etteplan Oyj ETTE.HE : Evli Research raises to buy from hold * Halma HLMA.L : Barclays raises target price to 284
B
C
E
H
H
J
L
O
O
P
R
S
S
T
U
V
V
Z
H
A
R

Dsm-firmenich sees boost as weight-loss drugs spur healthier choices

UPDATE 1-Dsm-firmenich sees boost as weight-loss drugs spur healthier choices Weight-loss drugs seen boosting demand for dietary supplements Preventive healthcare could raise interest in new ingredients Updates paragraph 12 to make it clear company is reviewing options including sale or IPO for Animal Nutrition division By Dimitri Rhodes and Matteo Allievi June 10 (Reuters) - The soaring popularity of weight-loss drugs are likely to spur demand for dietary supplements and healthier food formulat
G
K
L
S

Dsm-firmenich sees boost as weight-loss drugs spur healthier choices

Dsm-firmenich sees boost as weight-loss drugs spur healthier choices Weight-loss drugs seen boosting demand for dietary supplements Preventive healthcare could raise interest in new ingredients By Dimitri Rhodes and Matteo Allievi June 10 (Reuters) - The soaring popularity of weight-loss drugs are likely to spur demand for dietary supplements and healthier food formulations, creating growth opportunities for dsm-firmenich, the CEO of the flavours to nutrition company told Reuters.
G
K
L
S

DB sees Symrise 'earnings momentum turning a corner,' ups to 'buy'

BUZZ-DB sees Symrise 'earnings momentum turning a corner,' ups to 'buy' ** Deutsche Bank raises German flavour and fragrance maker Symrise SY1G.DE to "buy" from "hold," citing improved earnings momentum ** DB flags positive volume leverage and costs cuts, half of which kick in in H1 ** Although the company saw modest price pressure during Q1, it do
S

European shares decline as cautious Fed commentary weighs

UPDATE 2-European shares decline as cautious Fed commentary weighs For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window German wholesale prices fall 1.8% in April STOXX 600 down 0.6% Updated at 1600 GMT By Shashwat Chauhan and Khushi Singh May 28 (Reuters) - European shares f ell in broad-based declines on Tuesday in the lead-up to crucial inflation prints around the world this week, while cautious commentary from Federal Reserve officials fu
D
J
O
S
F
E
F
U
G

Argenx, Hermes, National Grid

EUROPE RESEARCH ROUNDUP- Argenx, Hermes, National Grid May 28 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Argenx, Hermes and National Grid, on Tuesday. HIGHLIGHTS * Argenx ARGX.BR : Barclays raises target price to EUR 375 from EUR 360 * Endomines Finland Oyj PAMPALO.HE : Evli Research raises to hold from sell * Hermes HRMS.PA : Bernstein raises to outperform from market perform * National Grid Plc NG.L : RBC cuts target price t
A
A
B
B
B
E
G
H
I
I
J
L
M
R
R
S
S
S
S
S
U
A
N
S



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.